Next earnings date: 7 Aug 2025

Edesa Biotech, Inc. – NASDAQ:EDSA

Add to watchlist

$2.32

+0.46

+25.41%

Market closed

Open in about 7 hours

-56.57%

month

-56.57%

quarter

-60.72%

year

Market Cap	6.41M
Enterprise value	3.47M

P/E	-1.12
EV/Sales	N/A
EV/EBITDA	-0.22
Price/Sales	N/A
Price/Book	1.12
PEG ratio	0.03
EPS	-2.65

Revenue	N/A
EBITDA	-8.26M
Income	-7.90M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Edesa Biotech, Inc. (NASDAQ:EDSA): Profit margin
Mar 2023	0	-2.33M
Jun 2023	0	-1.98M
Sep 2023	-1.11M	-1.72M	153.86%
Mar 2024	0	-1.86M

Edesa Biotech Financials Estimate

Q Y

Edesa Biotech, Inc. (NASDAQ:EDSA): Analyst Estimates
2025	0	-10.85M
2026	0	-14.2M
2027	19M	0
2028	49M	0

Analysts Price target
Financials & Ratios estimates

Edesa Biotech, Inc. (NASDAQ:EDSA): Earnings per share (EPS)
2024-08-09	-0.58	-0.52

Edesa Biotech, Inc. (NASDAQ:EDSA): Debt to assets
Mar 2023	10673485	1.67M	15.68%
Jun 2023	9419524	1.56M	16.66%
Sep 2023	8890437	1.84M	20.71%
Mar 2024	6475056	2.15M	33.22%

Edesa Biotech, Inc. (NASDAQ:EDSA): Cash Flow
Mar 2023	-1.57M	764.64K
Jun 2023	-1.80M	741.23K
Sep 2023	-1.46M	412.46K
Mar 2024	-1.67M	214.29K

Edesa Biotech alternative data

Edesa Biotech, Inc. (NASDAQ:EDSA): Employee count
Aug 2023	16
Sep 2023	16
Oct 2023	16
Nov 2023	16
Dec 2023	16
Jan 2024	16
Feb 2024	16
Mar 2024	16
Apr 2024	16
May 2024	16
Jun 2024	16
Jul 2024	16

Edesa Biotech
Hedge Funds Holdings Q1 2023

45.87% -54.13%

of EDSA is owned by hedge funds

15 -4

hedge funds hold EDSA stock

674.71K -957.28K

shares is hold by hedge funds

EDSA hedge funds holdings changes

Edesa Biotech, Inc. (NASDAQ:EDSA): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	5000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	25 Mar 2024	NIJHAWAN PARDEEP director, 10 percent owner, officer: Chie.. director, 10 percent owner, off..	Common Shares	5,000	$4	$20,000
Sale	10 Jan 2023	VAN DER VELDEN PETER director director	Common share	12,895	$2.64	$33,978
Sale	10 Jan 2023	VAN DER VELDEN PETER director director	Common share	139,450	$2.64	$367,451
Sale	9 Jan 2023	VAN DER VELDEN PETER 10 percent owner 10 percent owner	Common share	12,284	$2.66	$32,700
Sale	9 Jan 2023	VAN DER VELDEN PETER 10 percent owner 10 percent owner	Common share	132,845	$2.66	$353,633
Purchase	30 Jun 2022	NIJHAWAN PARDEEP director, 10 percent owner, officer: Chie.. director, 10 percent owner, off..	Common Shares	20,000	$1.6	$32,080
Purchase	29 Jun 2022	BROOKS MICHAEL J officer: President officer: President	Common Shares	3,000	$1.49	$4,482
Purchase	16 Jun 2022	BROOKS MICHAEL J officer: President officer: President	Common Shares	3,000	$1.61	$4,818
Purchase	27 May 2022	NIJHAWAN PARDEEP director, 10 percent owner, officer: Chie.. director, 10 percent owner, off..	Common Shares	5,000	$1.92	$9,600
Purchase	25 May 2022	BROOKS MICHAEL J officer: President officer: President	Common Shares	3,500	$1.74	$6,090

Edesa Biotech
Earnings Call Transcripts

Quarter	Transcript
Q4 2016 15 Dec 2016	Q4 2016 Earnings Call Transcript
Q3 2016 10 Aug 2016	Q3 2016 Earnings Call Transcript
Q2 2016 11 May 2016	Q2 2016 Earnings Call Transcript
Q1 2016 10 Feb 2016	Q1 2016 Earnings Call Transcript

EDSA earnings call transcripts

Edesa Biotech
Executives

Insider	Age	Compensation
Dr. Pardeep Nijhawan FRCPC, M.D. (1970) Chief Executive Officer, Company Sec. & Director	55	$498,770
Dr. Michael J. Brooks M.B.A., Ph.D. (1978) Pres	47	$446,090
Ms. Kathi Niffenegger CPA, CPA (1957) Chief Financial Officer	68	$435,920

Edesa Biotech
Latest News

Friday, 13 December 2024
16:30	Edesa Biotech Reports Fiscal Year 2024 Results	globenewswire.com
Thursday, 31 October 2024
08:15	Edesa Biotech's Founder Makes Strategic Investment in the Company	globenewswire.com
Monday, 21 October 2024
08:15	Edesa Biotech Announces Upcoming Conference Schedule	globenewswire.com
Friday, 13 September 2024
19:38	Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.	globenewswire.com
Friday, 9 August 2024
16:20	Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results	globenewswire.com
Monday, 24 June 2024
08:20	BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS	accesswire.com
Friday, 10 May 2024
16:15	Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results	accesswire.com
Thursday, 11 April 2024
09:00	Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	Accesswire
Tuesday, 2 April 2024
09:00	Edesa Biotech to Participate in Upcoming Investor Conferences	Accesswire
Thursday, 7 March 2024
08:45	Edesa Biotech to Participate in Barclays Global Healthcare Conference	Accesswire
Thursday, 26 October 2023
16:05	Edesa Biotech to Present at Dermatology Drug Development Summit	Accesswire
Thursday, 16 March 2023
16:10	Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	Accesswire
Friday, 30 September 2022
13:50	What Is Going on With Edesa Biotech (EDSA) Stock Today?	InvestorPlace
Thursday, 8 September 2022
16:30	Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference	Accesswire
Monday, 11 July 2022
08:30	Edesa Biotech to Present at ARDS Drug Development Summit	Accesswire
Thursday, 19 May 2022
16:30	Edesa Biotech to Present at H.C. Wainwright Global Investment Conference	Accesswire
Monday, 18 April 2022
13:53	Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD	Seeking Alpha
Thursday, 13 January 2022
09:55	Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy	Benzinga
Tuesday, 19 October 2021
15:45	Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions	Benzinga
09:32	Why Edesa Biotech Shares Are Trading Higher Today	Benzinga
08:00	Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study	Accesswire
Wednesday, 22 September 2021
14:57	Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients	Seeking Alpha
Monday, 20 September 2021
16:28	EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday	InvestorPlace
14:43	Why Edesa Biotech Shares Are Soaring Today	Benzinga
13:55	How To Play Edsa Biotech's Stock After 60% Surge	Benzinga
08:27	EDSA Stock: Why It Significantly Increased Today	Pulse2
08:00	Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients	Accesswire
Thursday, 26 August 2021
13:01	Edesa Biotech Provides Update For COVID-19 Antibody Trial	Benzinga
07:30	Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule	Accesswire
Friday, 13 August 2021
07:50	Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results	Accesswire

Frequently Asked Questions (FAQ)

What's the price of Edesa Biotech stock today?

One share of Edesa Biotech stock can currently be purchased for approximately $2.32.
When is Edesa Biotech's next earnings date?

Edesa Biotech, Inc. is estimated to report earnings on Thursday, 7 Aug 2025.
Does Edesa Biotech pay dividends?

No, Edesa Biotech does not pay dividends.
How much money does Edesa Biotech make?

Edesa Biotech has a market capitalization of 6.41M. Edesa Biotech made a loss 6.17M US dollars in net income (profit) last year or -$0.52 on an earnings per share basis.
What is Edesa Biotech's stock symbol?

Edesa Biotech, Inc. is traded on the NASDAQ under the ticker symbol "EDSA".
What is Edesa Biotech's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Edesa Biotech?

Shares of Edesa Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Edesa Biotech's key executives?
Edesa Biotech's management team includes the following people:
- Dr. Pardeep Nijhawan FRCPC, M.D. Chief Executive Officer, Company Sec. & Director(age: 55, pay: $498,770)
- Dr. Michael J. Brooks M.B.A., Ph.D. Pres(age: 47, pay: $446,090)
- Ms. Kathi Niffenegger CPA, CPA Chief Financial Officer(age: 68, pay: $435,920)
How many employees does Edesa Biotech have?

As Jul 2024, Edesa Biotech employs 16 workers.
When Edesa Biotech went public?

Edesa Biotech, Inc. is publicly traded company for more then 15 years since IPO on 21 Jun 2010.
What is Edesa Biotech's official website?

The official website for Edesa Biotech is edesabiotech.com.
Where are Edesa Biotech's headquarters?

Edesa Biotech is headquartered at 100 Spy Court, Markham, ON.
How can i contact Edesa Biotech?

Edesa Biotech's mailing address is 100 Spy Court, Markham, ON and company can be reached via phone at 289-800-9600.

Edesa Biotech, Inc.

edesabiotech.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

289-800-9600

100 Spy Court
Markham, ON L3R 5H6

CIK: 0001540159
ISIN: CA27966L3065
CUSIP: 27966L108